scholarly journals Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs

2014 ◽  
Vol 10 (7) ◽  
pp. 654-663 ◽  
Author(s):  
Joong Sup Shim ◽  
Jun O. Liu
Keyword(s):  
Anticancer Drugs ◽  
Drug Repositioning ◽  
Recent Advances ◽  
New Anticancer Drugs

Recent Advances in Drug Repurposing for Parkinson’s Disease

2019 ◽  
Vol 26 (28) ◽  
pp. 5340-5362 ◽  
Author(s):  
Xin Chen ◽  
Giuseppe Gumina ◽  
Kristopher G. Virga
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Discovery ◽  
De Novo ◽  
Drug Repositioning ◽  
Drug Repurposing ◽  
Cost Effective ◽  
New Drugs ◽  
Recent Advances ◽  
Clinical Drugs

:As a long-term degenerative disorder of the central nervous system that mostly affects older people, Parkinson’s disease is a growing health threat to our ever-aging population. Despite remarkable advances in our understanding of this disease, all therapeutics currently available only act to improve symptoms but cannot stop the disease progression. Therefore, it is essential that more effective drug discovery methods and approaches are developed, validated, and used for the discovery of disease-modifying treatments for Parkinson’s disease. Drug repurposing, also known as drug repositioning, or the process of finding new uses for existing or abandoned pharmaceuticals, has been recognized as a cost-effective and timeefficient way to develop new drugs, being equally promising as de novo drug discovery in the field of neurodegeneration and, more specifically for Parkinson’s disease. The availability of several established libraries of clinical drugs and fast evolvement in disease biology, genomics and bioinformatics has stimulated the momentums of both in silico and activity-based drug repurposing. With the successful clinical introduction of several repurposed drugs for Parkinson’s disease, drug repurposing has now become a robust alternative approach to the discovery and development of novel drugs for this disease. In this review, recent advances in drug repurposing for Parkinson’s disease will be discussed.

Anti-Diarrheal Drug Repositioning in Tumour Cell Cytotoxicity

2019 ◽  
Vol 19 (8) ◽  
pp. 1037-1047 ◽  
Author(s):  
Jihene Elloumi-Mseddi ◽  
Dhouha Msalbi ◽  
Raouia Fakhfakh ◽  
Sami Aifa
Keyword(s):  
Side Effects ◽  
Anticancer Drugs ◽  
Tumour Cell ◽  
Caspase 3 ◽  
Drug Repositioning ◽  
Brdu Incorporation ◽  
Drug Concentrations ◽  
Significant Difference ◽  
Ic50 Values ◽  
Mcf 7

Background:Drug repositioning is becoming an ideal strategy to select new anticancer drugs. In particular, drugs treating the side effects of chemotherapy are the best candidates.Objective:In this present work, we undertook the evaluation of anti-tumour activity of two anti-diarrheal drugs (nifuroxazide and rifaximin).Methods:Anti-proliferative effect against breast cancer cells (MDA-MB-231, MCF-7 and T47D) was assessed by MTT analysis, the Brdu incorporation, mitochondrial permeability and caspase-3 activity.Results:Both the drugs displayed cytotoxic effects on MCF-7, T47D and MDA-MB-231 cells. The lowest IC50 values were obtained on MCF-7 cells after 24, 48 and 72 hours of treatment while T47D and MDA-MB-231 were more resistant. The IC50 values on T47D and MDA-MB-231 cells became significantly low after 72 hours of treatment showing a late cytotoxicity effect especially of nifuroxazide but still less important than that of MCF-7 cells. According to the IC50 values, the non-tumour cell line HEK293 seems to be less sensitive to cytotoxicity especially against rifaximin. Both the drugs have shown an accumulation of rhodamine 123 as a function of the rise of their concentrations while the Brdu incorporation decreased. Despite the absence of a significant difference in the cell cycle between the treated and non-treated MCF-7 cells, the caspase-3 activity increased with the drug concentrations rise suggesting an apoptotic effect.Conclusion:Nifuroxazide and rifaximin are used to overcome the diarrheal side effect of anticancer drugs. However, they have shown to be anti-tumour drugs which make them potential dual effective drugs against cancer and the side effects of chemotherapy.

Pt(II) vs Pd(II) Polyamine Complexes as New Anticancer Drugs: A Structure- Activity Study

2006 ◽  
Vol 3 (3) ◽  
pp. 149-151 ◽  
Author(s):  
S. Fiuza ◽  
A. Amado ◽  
Paulo Oliveira ◽  
Vilma Sardao ◽  
L. de Carvalho ◽  
...  
Keyword(s):  
Anticancer Drugs ◽  
Structure Activity ◽  
New Anticancer Drugs

In the Search for New Anticancer Drugs, III+ Phosphorylated Diaziridine Derivatives

1983 ◽  
Vol 38 (7) ◽  
pp. 884-894 ◽  
Author(s):  
George Sosnovsky ◽  
Jan Lukszo
Keyword(s):  
Anticancer Drugs ◽  
New Anticancer Drugs

Abstract Several N-diethoxyphosphoryl derivatives 7 of various diaziridines, and compounds 12, 15a, 15b, 18 and 20, structurally related to TEPA (1a) and spin labeled Thio-TEPA (1c) were synthesized.

Seleno-l-methionine and l-ascorbic acid differentiate the biological activity of doxorubicin and its metal complexes as a new anticancer drugs candidate

2018 ◽  
Vol 48 ◽  
pp. 141-148 ◽  
Author(s):  
Marzena Matejczyk ◽  
Grzegorz Świderski ◽  
Renata Świsłocka ◽  
Stanisław Józef Rosochacki ◽  
Włodzimierz Lewandowski
Keyword(s):  
Ascorbic Acid ◽  
Biological Activity ◽  
Metal Complexes ◽  
Anticancer Drugs ◽  
New Anticancer Drugs
Sign in / Sign up

Export Citation Format

Share Document